Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats

The tyrosine kinase inhibitor sorafenib is the first-line treatment for patients with hepatocellular carcinoma (HCC), in which hyperlipidemia and type 2 diabetes mellitus (T2DM) may often coexist. Protein transporters like organic cation (OCT) and multidrug and toxin extrusion (MATE) are involved in...

Descripción completa

Detalles Bibliográficos
Autores principales: Karbownik, Agnieszka, Szkutnik-Fiedler, Danuta, Czyrski, Andrzej, Kostewicz, Natalia, Kaczmarska, Paulina, Bekier, Małgorzata, Stanisławiak-Rudowicz, Joanna, Karaźniewicz-Łada, Marta, Wolc, Anna, Główka, Franciszek, Grześkowiak, Edmund, Szałek, Edyta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408095/
https://www.ncbi.nlm.nih.gov/pubmed/32605304
http://dx.doi.org/10.3390/pharmaceutics12070600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408095/
https://www.ncbi.nlm.nih.gov/pubmed/32605304
http://dx.doi.org/10.3390/pharmaceutics12070600

Ejemplares similares